About PSC. PSC is a biopharmaceutical company, whose mission it is to save lives and improve health by effectively responding to our changing world with innovative vaccines and biopharmaceuticals. PSC uses recombinant DNA technology to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. The active ingredients in all of the firm's products are recombinant proteins that are manufactured, using its patented protein expression technology, based upon baculovirus and insect cell technology.
In response to the current health emergency declared by the Department of Health and Human Services, PSC is developing a vaccine for the potential pandemic swine flu (PanBlok(R)) and expects to be manufacturing the vaccine within six weeks and to be able to produce 20,000 to 30,000 doses per week.
The Company's lead product is FluBlok(R), a seasonal recombinant trivalent influenza vaccine, consisting of influenza hemagglutin (HA) proteins. FluBlok is manufactured without the use of eggs, is highly purified and therefore does not require the use of thimerosal or antibiotics and is low in endotoxins. PSC filed a Biologics License Application for FluBlok with the FDA in
Our web site is (www.proteinsciences.com)
SOURCE Protein Sciences Corporation